Adverse drug reactions related to the use of fluoroquinolone antimicrobials: An analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions

Drug Safety

Volumn 26, Issue 2, 2003, Pages 109-120

  Leone, Roberto ^a,f   Venegoni, Mauro ^b   Motola, Domenico ^c   Moretti, Ugo ^a   Piazzetta, Valentina ^a   Cocci, Alfredo ^d   Resi, Domenico ^c   Mozzo, Federico ^a   Velo, Giampaolo ^a   Burzilleri, Liliana ^e   Montanaro, Nicola ^c   Conforti, Anita ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d ASL   (Italy)

^e Lombardy Centre of Pharmacovigilance   (Italy)

^f Clinical Pharmacology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CIPROFLOXACIN; CORTICOSTEROID; ENOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUFLOXACIN; SEROTONIN UPTAKE INHIBITOR; WARFARIN;

ACHILLES TENDON RUPTURE; ACUTE KIDNEY FAILURE; ANGIONEUROTIC EDEMA; ANTIBIOTIC THERAPY; ARTHROPATHY; ARTICLE; BLEEDING DISORDER; BONE DISEASE; CONTROLLED STUDY; CONVULSION; CORRELATION ANALYSIS; CRYSTALLURIA; DEMOGRAPHY; DROWSINESS; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HEMATURIA; HUMAN; INSOMNIA; INTERNATIONAL STANDARD UNIT; INTERSTITIAL NEPHRITIS; ITALY; KIDNEY DYSFUNCTION; LIVER TOXICITY; MENTAL DISEASE; MUSCLE DISEASE; NEUROTOXICITY; NONHUMAN; PHOTOALLERGY; PHOTOSENSITIVITY DISORDER; PHOTOTOXICITY; PRIORITY JOURNAL; PSYCHOSIS; QT INTERVAL; SEX RATIO; SKIN DISEASE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TENDINITIS; TENDON DISEASE; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; TOXICITY; VERTIGO;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; AGED; ANTI-INFECTIVE AGENTS; BRAIN; CHILD; CHILD, PRESCHOOL; FLUOROQUINOLONES; HUMANS; INFANT; INFANT, NEWBORN; ITALY; KIDNEY; MIDDLE AGED; TENDINOPATHY;

EID: 0037272414     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326020-00004     Document Type: Article

References (80)

1. Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002; 65: 455-64
2. King DE, Malone R, Lilley SH. New classification and update on the quinolone antibiotics. Am Fam Physician 2000; 61: 2741-7
3. Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000; 46: 17-24
4. Lee MK, Katani MS. Quinolones: which generation for which microbe? West J Med 1999; 170: 359-61
5. Ball P, Mandell L, Niki Y, et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999; 21 (5): 407-21
6. Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001; 47 Suppl. 3: 3-8
7. Andriole VT. The future of the quinolones. Drugs 1999; 58 Suppl. 2: 1-5
8. Bowie WR, Willetts V, Jewesson PJ. Adverse reaction in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother 1989; 33: 1778-82
9. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994; 18: 946-50
10. Norrby SR, Pernet AG. Assessment of adverse events during drug development: experience with temafloxacin. J Antimicrob Chemother 1991; 28 Suppl. C: 111-9
11. U.S. Food and Drug Administration. Glaxo Wellcome voluntary withdraws Raxar (Grepafloxacin). Press release: 1999 Oct 27 [online]. Available from URL: http://www.fda.gov/medwatch/safety/1999/raxar.html [Accessed 2002 May 15]
12. The European Agency for the Evaluation of Medicinal Products. Human Medicines Evaluation Unit. Public statement on trovafloxacin/alatrofloxacin. Press release: 1999 Jun 15 [online]. Available from URL: http://www.emea.eu.int/pdfs/human/press/pus/1804699EN.pdf [Accessed 2002 May 21]
13. Tillotson GS, Rybak MG. New milestones achieved in fluoroquinolone safety. Pharmacotherapy 2001; 21: 358-60
14. Domagala JM. Structure activity and structure-side-effect relationship for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685-706
15. Mandell LA, Ball P, Tillotson G. Antimicrobial safety and tolerability: differences and dilemmas. Clin Infect Dis 2001; 32 Suppl. 1: S72-9
16. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28: 352-64
17. Lode H. Evidence of different profiles of side effects and drug-drug interactions among the quinolones: the pharmacokinetic standpoint. Chemotherapy 2001; 47 Suppl. 3: 24-31
18. Iannini PB, Tillotson GS. Evaluating the risk of cardiac toxicity. Pharmacotherapy 2001; 21: 261-2
19. Meyboom RHB, Egberts ACG, Gribnau FWJ, et al. Pharmacovigilance in perspective. Drug Saf 1999; 21: 429-47
20. Pierfitte C, Bégaud B, Lagnaoui R, et al. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol 1999; 47: 329-31
21. Figueras A, Capellà D, Castel JM, et al. Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1994; 47: 297-303
22. Carvajal A, Prieto JR, Requejo AA, et al. Aspirin or acetaminophen: a comparison from data collected by the Spanish Drug Monitoring System. J Clin Epidemiol 1996; 49: 255-61
23. Wiholm BE, Emanuelsson S. Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994. Eur J Haematol Suppl. 1996; 60: 42-6
24. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors. Reports from a spontaneous reporting system. Drug Saf 1999; 20 (3): 277-87
25. Routledge PA, Lindquist M, Edwards IR. Spontaneous reporting of suspected adverse reactions to antihistamines: a national and international perspective. Clin Exp Allergy 1999; 29: 240-6
26. Conforti A. Leone R, Moretti U, et al. Adverse drug reactions related the use of NSAIDs with a focus on nimesulide. Drug Saf 2001; 24 (14): 1081-90
27. Carvajal GP, Garcia D, Sanchez SA, et al. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 2002; 63: 135-7
28. Uppsala Monitoring Centre. Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. Uppsala: The Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, 2000
29. Olsson S. Role of WHO programme on international drug monitoring in co-ordinating world-wide drug safety efforts. Drug Saf 1998; 19 (1): 1-10
30. Strom BL. What is pharmacoepidemiology? In: Strom BL, editor. Pharmacoepidemiology, 3rd ed. Chichester: John Wiley, 2000: 3-15
31. Edwards IR. Spontaneous reporting of what? Clinical concerns about drugs. Br J Clin Pharmacol 1999; 48: 138-41
32. Meyboom RHB, Egberts ACG, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16 (5): 355-65
33. Vaccheri A, Castelvetri E, Esaka A, et al. Pattern of antibiotic use in primary health care in Italy. Eur J Clin Pharmacol 2000; 56: 417-25
34. Nicolle LE. Quinolones in the aged. Drugs 1999; 58 Suppl. 2: 49-51
35. Bem JL, Mann RD, Rawlins MD. CSM update: review of yellow cards: 1986 and 1987 [brief update]. BMJ 1988; 296: 1319
36. Ochsenfahrt H, Meyer zur Heyde M. Spontaneous reports on unwanted drug effects in the years 1978-1979. Fortschr Med 1981; 99: 1753-8
37. Moore N, Noblet C, Kreft-Jais C, et al. French pharmacovigilance database system: examples and utilisation. Therapie 1995; 50: 557-62
38. Figueras A, Capella D, Castel JM, et al. Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs: a report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations. Eur J Clin Pharmacol 1994; 47: 297-303
39. Faich GA, Knapp D, Dreis M, et al. National adverse drug reaction surveillance: 1985. JAMA 1987; 257: 2068-70
40. Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs: an analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48: 839-46
41. Istituto Nazionale di Statistica. Sistema sanitario e salute della popolazione (second edition) [online]. Available from URL: http://www.istat.it/Banche-dat/Indicatori/01/tavole.zip [Accessed 2002 May 6]
42. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21 (10 Suppl.): 253S-272S
43. Moretti MV, Pauluzzi S, Cesana M. Penetration of rufloxacin into the cerebrospinal fluid in patients with inflamed and uninflamed meninges. Antimicrob Agents Chemother 2000; 44: 73-7
44. De Sarro A, Cecchetti V, Fravolini V, et al. Effects of novel 6-desfluoroquinolones and classic quinolones on pentylenetetrazole-induced seizures in mice. Antimicrob Agents Chemother 1999; 43: 1729-36
45. Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999; 58 Suppl. 2: 37-42
46. Ball P, Tillotson G. Tollerability of fluoroquinolone antibiotics. Drug Saf 1995; 13 (6): 343-58
47. Wagai N, Yamaguchi F, Sekiguchi M, et al. Phototoxic potential of quinolone antibacterial agents in Balb/c mice. Toxicol Lett 1990; 54: 299-300
48. Snyder RD, Cooper CS. Photogenotoxicity of fluoroquinolones in Chinese hamster V79 cells: dependency on active topoisomerase II. Photochem Photobiol 1999; 69: 288-93
49. Klimberg IWS, Cox CE, Fowler CL, et al. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology 1998; 51: 610-5
50. Lowe NJ, Fakouhi TD, Stern RS, et al. Photoreactions with a fluoroquinolone antimicrobial: evening versus morning dosing. Clin Pharmacol Ther 1994; 56: 587-91
51. Iannini PB. Prolongation of QT interval is probably a class effect of fluoroquinolones [letter]. BMJ 2001; 322: 46
52. Clark DWJ, Layton D, Wilton LV, et al. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials. Drug Saf 2001; 24 (15): 1143-54
53. Stahlmann F. Safety profile of the quinolones. J Antimicrob Chemother 1990; 26 Suppl. D: 31-44
54. Lee WT, Collins JF. Ciprofloxacin associated bilateral Achilles tendon rupture. Aust N Z J Med 1992; 22: 500
55. Ribard P, Audisio F, Kahn MF, et al. Seven Achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy. J Rheumatol 1992; 19: 1479-81
56. Huston KA. Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics [letter]. N Engl J Med 1994; 331: 748
57. Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture [letter]. N Engl J Med 1995; 332: 193
58. Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie 1996; 51: 419-20
59. Zabraniecki L, Negrier I, Vergne P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol 1996; 23: 516-20
60. McGarvey WC, Singh D, Trevino SG. Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. Foot Ankle Int 1996; 17: 496-8
61. Carrasco JM, Garcia B, Andujar C, et al. Tendinitis associated with ciprofloxacin [letter]. Ann Pharmacother 1997; 31: 120
62. Schwald N, Debray Meignan S. Suspected role of ofloxacin in a case of arthralgia myalgia, and multiple tendinopathy. Rev Rhum Engl Ed 1999; 66: 419-21
63. Lewis JR, Gums JG, Dickensheets DL. Levofloxacin-induced bilateral Achilles tendinitis. Ann Pharmacother 1999; 33: 792-5
64. Fleisch F, Hartmann K, Kuhn M. Fluoroquinolone-induced tendinopathy: also occurring with levofloxacin. Infection 2000; 28: 256-7
65. van der Linden PD, van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Care Res 2001; 45: 235-9
66. van der Linden PD, van de Lei J, Nab HW, et al. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 1999; 48: 433-7
67. van der Linden PD, Nab HW, Simonian S, et al. Fluoroquinolone use and the change in incidence of tendon ruptures in the Netherlands. Pharm World Sci 2001; 23: 89-92
68. van der Linden PD, Sturkenboom MCJM, Herings RMC, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324: 1306-7
69. Lomaestro BM. Fluoroquinolone-induced renal failure. Drug Saf 2000; 22 (6): 479-85
70. Schluter G. Ciprofloxacin: review of potential toxicologic effects. Am J Med 1987; 82 Suppl. 4A: 91-3
71. Mott FE, Murphy S, Hunt V. Ciprofloxacin and warfarin. Ann Intern Med 1989; 3: 542-3
72. Kamada AK. Possible interaction between ciprofloxacin and warfarin. Ann Pharmacother 1990; 24: 27-8
73. Johnson KC, Joe RH, Self TH. Drug interaction [letter]. J Fam Pract 1991; 33: 338
74. Dugoni-Kramer BM. Ciprofloxacin-warfarin interaction [letter]. Ann Pharmacother 1991; 25: 1397
75. Jolson HM, Tanner LA, Green L, et al. Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch Intern Med 1991; 151: 1003-4
76. Ellis RJ, Mayo MS, Bodensteiner DM. Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 2000; 63: 28-31
77. Linville T, Matanin D. Norfloxacin and warfarin. Ann Intern Med 1989; 110: 751-2
78. Baciewicz AM, Ashar BY, Locke TW. Interaction of ofloxacin and warfarin [letter]. Ann Intern Med 1993; 119: 1223
79. Ravnan SL, Locke C. Levofloxacin and warfarin interaction. Pharmacotherapy 2001; 21: 884-5
80. Gheno G, Cinetto L. Levofloxacin-warfarin interaction [letter]. Eur J Clin Pharmacol 2001; 57: 427